Drugs Medical Pharma

Merck discontinues trial for combo cancer drug for melanoma

HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.

Read More
Drugs Health Pharma

Merck’s end-stage trials of endometrial cancer therapy fail to meet goals

HQ Team May 9, 2024: Merck announced that its Phase 3 trial evaluating Keytruda therapy in combination with chemotherapy, with or without radiotherapy,.

Read More
Drugs Medical Pharma

Merck’s Keytruda receives FDA nod for cervical cancer treatment

HQ Team January 13, 2024: The U.S. Food and Drug Administration (FDA) has granted approval for the expanded use of Merck & Co’s.

Read More
Drugs Medical Pharma

Moderna’s melanoma vaccine shows promise in clinical trials

HQ Team December 23, 2023: Moderna unveiled a skin cancer vaccine that demonstrated promising results in recent clinical trials. The vaccine, administered in.

Read More
Drugs Health Pharma

USFDA green lights Merck’s drug to treat advanced kidney cancer 

HQ Team December 15, 2023: Merck announced it got USFDA approval for its belzutifan drug, branded as Welireg, to treat an advanced form.

Read More
Drugs Health Pharma

Merck gets priority review nod from USFDA for hypertension drug 

HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

Read More
Drugs Health Pharma

Anixa to conduct breast cancer trials with Merck’s Keytruda therapy

HQ Team August 7, 2023: Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to.

Read More
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More
Drugs Health Pharma

FDA applies brakes on Merck’s multiple sclerosis drug tests

HQ Team April 13, 2023: Merck KGaA announced the USFDA had put a hold on the initiation of new patients to test its.

Read More
Drugs Pharma

Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designation 

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.

Read More
X